Valuation
- Market cap
- 49,934,000
- Revenue TTM
- $0
- Net income TTM
- $-28,850,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 648,500
- Avg volume
- 940,260
- Day's range
- $1.14 – $1.20
- Shares out
- 42,679,000
- Stochastic %K
- 15%
- Beta
- 1.23
- Analysts
- Strong Sell
- Price target
- $10.50
Company profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and A...
Show more
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 484 875 3192
- Website
- https://www.annovisbio.com
- Address
- 101 Lindenwood Drive, Suite 225, Malvern, United States
Latest news
No headlines yet.
